Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interleukin-6 and rheumatic diseases.

Peter E Lipsky1

  • 1Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Rockville Pike, Bethesda, Maryland, USA. lipskyp@mail.nih.gov

Arthritis Research & Therapy
|August 11, 2006
PubMed
Summary

Interleukin-6 (IL-6) plays a key role in autoimmune diseases. Blocking IL-6 signaling, potentially with tocilizumab, may offer significant therapeutic benefits for patients with rheumatic diseases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An NT5E loss-of-function variant permits tissue inflammation and hypertension in systemic lupus erythematosus.

iScience·2026
Same author

Genes causative of primary immunodeficiency are risk factors for and are over-expressed in systemic lupus erythematosus.

Frontiers in immunology·2026
Same author

Subsets of Patients With Lupus Identified by Gene Expression Profiles Exhibit Differential Clinical Responsiveness to Baricitinib.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

Reply.

Arthritis & rheumatology (Hoboken, N.J.)·2025
Same author

20 years of Nature Reviews Rheumatology.

Nature reviews. Rheumatology·2025
Same author

Pain in systemic lupus erythematosus: emerging insights and paradigms.

Nature reviews. Rheumatology·2025

Area of Science:

  • Immunology
  • Rheumatology
  • Cytokine Signaling

Background:

  • Interleukin-6 (IL-6) is a pleiotropic cytokine crucial for inflammatory and immunologic responses.
  • Elevated levels of IL-6 and its soluble receptor (sIL-6Ralpha) are observed in various rheumatic diseases.

Purpose of the Study:

  • To explore the dual role of IL-6 in disease initiation and maintenance.
  • To evaluate the potential therapeutic benefits of blocking IL-6 signaling in rheumatic diseases.

Main Methods:

  • Review of existing literature on IL-6 function in autoimmune and rheumatic diseases.
  • Analysis of the impact of IL-6 blockade in experimental models and human studies.

Main Results:

  • IL-6 is implicated in both the onset and persistence of autoimmune inflammation.
  • IL-6 blockade demonstrates efficacy in preclinical models and clinical settings.
  • Elevated IL-6 and sIL-6Ralpha correlate with disease severity in rheumatic conditions.

Conclusions:

  • Targeting IL-6 offers a promising therapeutic strategy for rheumatic diseases.
  • Inhibition of IL-6 signaling, for example with tocilizumab, may prevent or reverse disease complications.
  • Dual blockade of IL-6 functions could provide additive or unique clinical benefits.

Related Experiment Videos